about
Mechanism of inositol monophosphatase, the putative target of lithium therapySelective labelling of diazepam-insensitive GABAA receptors in vivo using [3H]Ro 15-4513Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding siteThe in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagocloneThe 5HT(1B) receptor agonist, CP-93129, inhibits [(3)H]-GABA release from rat globus pallidus slices and reverses akinesia following intrapallidal injection in the reserpine-treated ratDifferent GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primatesReducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes.Cocaine effects on mouse incentive-learning and human addiction are linked to alpha2 subunit-containing GABAA receptors.Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype.Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux.6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABA-A alpha5 receptor inverse agonists.Subtype-selective GABAergic drugs facilitate extinction of mouse operant behaviour.Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site.In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330.An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.A new pyridazine series of GABAA alpha5 ligands.TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates.An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition.An inverse agonist selective for alpha5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze.L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents.Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands.Development of an oligonucleotide-based fluorescence assay for the identification of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors.Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the α7 nicotinic acetylcholine receptor.GABA(A) Receptor Subtypes: Novel Targets for Novel MedicinesCharacterization of [35S]t-butylbicyclophosphorothionate ([35S]TBPS) binding to GABAA receptors in postmortem human brainThe complexity of the GABAA receptor shapes unique pharmacological profiles.Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA.GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics.Lipophilic nalmefene prodrugs to achieve a one-month sustained release.Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones as alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.Detection of gender differences in rat lens proteins using 2-D-DIGE.3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1.Structure and mechanism of inositol monophosphatase.3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels.Cell surface expression of the human N-methyl-D-aspartate receptor subunit 1a requires the co-expression of the NR2A subunit in transfected cells.The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primatesMode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2.Characterization of the effects of lithium on phosphatidylinositol (PI) cycle activity in human muscarinic m1 receptor-transfected CHO cells.
P50
Q24562775-5BB56F8F-D48E-4AAD-8A49-E5118EE2359EQ24676214-71CD7127-11D5-4783-B10C-CBE2A7F680EBQ28188111-8B389335-F112-4391-8C33-5C8AA29A278CQ28293295-B49955EF-EB41-428E-827B-6A4A00E9C5CFQ28344635-0F56ADD2-4A2F-4B60-BE43-2E0B6705D281Q30854476-8FACAEEE-4A76-4EA5-9781-CE2C213E84DDQ33574884-D918FB14-3EE0-422F-8998-05846CDBE0B5Q33719824-95DE7655-FD0E-4794-9FC4-BF8E15970075Q33902217-AC0922CE-429F-481D-B21C-14D0FA020AF4Q33942784-942E3971-BCAF-479F-8423-6BE9443EA3A4Q34117268-82D3DD1D-B82C-4C9C-954E-95EDC7DAEB40Q34284426-80ECD895-E650-4F8A-AAC6-97C60D8DDBC1Q34313484-180C6C76-C5C3-41A7-9211-9CA9E68013ABQ34328765-C943FDBA-98C1-45F8-915B-F85655908D4DQ34355076-C8A32D38-4DC7-4A1E-8ECD-3AEEF0DF7A68Q34366742-229BE09B-60B5-498A-8E15-AAE9AD28CA0FQ34450828-341500D6-F107-4F5F-A08A-94E1AE3983DCQ34453763-092C08A9-AAE0-4C78-B846-FA4990C4A5B3Q34472772-692D479B-4A88-4024-B60F-0CCB069F3028Q34516852-864EBEA0-628A-4080-9E50-E06DF2588D1BQ34574461-6A0F8CEC-77A8-439F-8252-4095428DFAD6Q34576043-AA6241D9-AA23-4112-A0C1-F21A59E4E511Q34580275-28CDCEA2-0F08-4BD9-BD3A-C0B83E40AE34Q35122653-AE45BEC1-A108-45E7-AF37-A57B0D768012Q35616147-555EE071-4A92-45A5-AD31-8E9F530008D7Q35915274-8FEEFC12-A033-4E13-AD09-5C1A7766E0DEQ36052617-89AD3F46-3A57-4285-9C9B-6D3F89D724EFQ37540906-4F2BC967-BF36-480D-9353-695FC6DEA84AQ37601045-510C5130-A41B-40EC-84AD-2CAEE46A9881Q37807058-D3EF43F2-DFBB-4877-AAE4-736953D1EC96Q39827843-C6032808-9633-4792-A648-65870F0D4B6EQ40335345-441F6F87-30CF-475C-BB19-6EC14FB4A3AAQ40366151-B5294E92-BDA4-4A88-A800-64BF217AD55FQ40577363-158E6BFA-0BED-4B8A-B28A-850DBE2E08E2Q40612659-908FB98C-DA40-4D3A-95C7-82CBE48859EDQ40737346-4EF45076-3217-4D8E-AE0B-C765E063183AQ41230999-0FCE471E-EA89-468D-B0E8-240B28A265AFQ41932065-5A4C13D0-FC98-4DCF-8E0E-A845114EC28FQ42181420-EB8A91B1-43DF-46FB-BCD6-B1D47DD3E110Q42502826-3626B985-32F2-483C-92BB-F27F8D997F32
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John Atack
@ast
John Atack
@en
John Atack
@es
John Atack
@nl
type
label
John Atack
@ast
John Atack
@en
John Atack
@es
John Atack
@nl
prefLabel
John Atack
@ast
John Atack
@en
John Atack
@es
John Atack
@nl
P106
P1153
7005478065
P31
P496
0000-0002-3410-791X